Update on Current Medications for TS and Associated Disorders

Presenter: Dr. Roger Kurlan

View the webinar’s corresponding slide presentation here Download this webinar

Dr. Kurlan discusses the medications that are commonly prescribed, those prescribed in the past and still used today as well as medications new to the market.


  1. Rebecca Shiner says

    Will you be posting the sound to accompany the slides?

    • KelleyT says

      Ms. Shiner,

      The audio presentation will be posted to our website by end of day tomorrow.

  2. KelleyT says

    About Intunive: We have been told that it is superior to Tenex due to its once a day dose, whereas Tenex needs to be given multiple times a day. Can you explain more about once a day dosing of tenex?

    • Dr. Roger Kurlan says

      Tenex also only needs to be given once daily (usually at bedtime). There is no advantage of Intuniv, it is more expensive and has unpredictable absorption into the bloodstream/brain.

  3. KelleyT says

    Why is Intuniv not recommended?

  4. KelleyT says

    What is your experience with SSRIs causing suicidal ideation in older adolescents with TS & OCD?

    • Dr. Roger Kurlan says

      Suicidal ideation can sometimes occur during the first few weeks/months of SSRI treatment. Those with TS, OCD do not have any more risk for this problem.

  5. KelleyT says

    Your thoughts on medical marijuana, hemp oil or cbd oils – are any effective?

    • Dr. Roger Kurlan says

      There is little research on marijuana, hemp oil, cbd oil. They may indirectly lessen tics by relaxing the individual using them, but there is no current evidence that they directly suppress tics.

  6. KelleyT says

    What has been your experience with gabapentin for anxiety?

    • Dr. Roger Kurlan says

      Gabapentin is not a particularly useful medication for anxiety.

  7. KelleyT says

    How does CBT benefit an essentially reflexive disorder?

    • Dr. Roger Kurlan says

      OCD is not “reflexive”

  8. KelleyT says

    We had success with the weight gain/metabolic disorder using Metformin while on Abilify, as an anti-weight gain medication. Is that recommended?

    • Dr. Roger Kurlan says

      This would be a question for a pediatrician or Internist.

  9. KelleyT says

    many pharmacological references recommend giving larger doses of guanfacine by breaking it up; ie….three times a day. ex. 6mg for an adolescent. Break it up to 2mg tid or 3mg bid. For larger doses in larger patients, is the once daily at night still appropriate at max doses?

    • Dr. Roger Kurlan says

      Tenex is given in doses of 1-4mg/day. A single bedtime dose is fine for this dose range.

  10. KelleyT says

    Some schools want to classify TS as a mental illness. But it is a neurobiological disorder. Do you categorize it as a cross -over disorder, mental disorder or neurological disorder?

    • Dr. Roger Kurlan says

      I classify TS as a medical/neurological disorder.

  11. KelleyT says

    Have any genes been identified related to TS?

  12. KelleyT says

    I’m listening to the webinar. I have a 30 year old son with ts. Abilify was a miracle drug for him but he has gained a lot of weight from it. Would the new drug ingrezza possibly be an alternative medication for Abilify?

  13. Admin says

    Your thoughts please on keppra and orap?

    • Dr. Roger Kurlan says

      Orap is a classical antipychotic. It is almost never prescribed anymore because it can adversely affect the heart rhythm and long term EKG monitoring is needed. The other antipsychotics do not carry this risk. There are some anecdotal reports of Keppra reducing tics, but there is little research evidence.

  14. Admin says

    Interested in your comment/thoughts: the MOA of AP’s (risperidone) causes hyperprolactinemia with concomitant hypotestosterone. The symptoms include total impotence, loss of libido (in 96% of pts) and a life threateningly drop in free and total testosterone.

    • Dr. Roger Kurlan says

      All antipsychotics raise prolactin levels and this is rarely a problem.

Comments are now closed for this article.